Kabisch, Maria
Novo Nordisk (Denmark)
3 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 814
- Verified
Once-Weekly Semaglutide 7·2 Mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 119
- Verified
1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial
WHARTON, S., FREITAS, P., HJELMESÆTH, J., KABISCH, M., KANDLER, K., LINGVAY, I., DE LOS ANGELES QUIROGA, M., ROSENSTOCK, J., & GARVEY, W. T. (. (2025) · Diabetes
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free